![]() | |
![]() A vial of Covaxin | |
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Trade names | Covaxin |
Routes of administration | Intramuscular |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
DrugBank | |
UNII |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
![]() |
Covaxin (development name, BBV152) is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.[1]
On 3 November 2021, the World Health Organization (WHO) validated the vaccine for emergency use, as the first Indian-developed covid vaccine to be approved.[2][3] By 31 January 2022, Covaxin had been granted emergency use approval in 13 countries.[4]